Minghui Pharmaceutical has announced an exclusive licensing and partnership agreement with Qilu Pharmaceutical for developing, manufacturing, and commercialising MHB088C in Greater China.
Under the deal, Qilu will have exclusive rights to the therapy in Mainland China, Macau, Taiwan, and Hong Kong.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataMeanwhile, Minghui is qualified for up to 1.345bn yuan ($185m), including an upfront payment of 280m yuan and a near-term milestone payment.
Additionally, the agreement stipulates up to 1.065bn yuan in development, regulatory, and sales milestone payments, along with double-digit royalties on net sales of the product.
Minghui will maintain global rights to the therapy outside Greater China and will progress the development of the therapy in these areas.
B7-H3-targeted antibody-drug conjugate (ADC), MHB088C, is developed leveraging Minghui’s SuperTopoi ADC platform.
The pharmaceutical company noted that in ongoing Phase I/II trials, the therapy was assessed in more than 300 individuals with advanced or metastatic solid tumours.
The trials have shown a favourable safety profile and efficacy. Moreover, a Phase III trial in relapsed small cell lung cancer (SCLC) has commenced in China, with the first subject expected to be enrolled shortly.
Minghui Pharmaceutical CEO Dr Guoqing Cao said: “Our collaboration with Qilu marks a significant milestone in Minghui’s commitment to advancing innovative cancer therapies.
“MHB088C has demonstrated robust efficacy with great safety profiles, with no major haematological toxicity or ILD, positioning the programme as a best-in-class B7-H3 ADC. With Qilu’s leadership and resources, we are confident that MHB088C will serve patients in need and contribute to the advancement of precision oncology in China.”
The company focuses on creating medicines for oncology and autoimmune conditions.
With a clinical-stage pipeline that includes ADC programmes and a programmed cell death protein 1x vascular endothelial growth factor (PD-1xVEGF) bispecific antibody, Minghui is progressing the therapy development to enhance patient outcomes globally.
Qilu Pharmaceutical, a vertically integrated pharmaceutical company in China, specialises in the development, manufacturing, and distribution of finished dosage forms (FDFs) and active pharmaceutical ingredients (APIs).
ADC content on Pharmaceutical Technology (Or Clinical Trials Arena) is supported by Syngene. Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
